September 30, 2026
4-Phenyl-2-Oxazolidinone (R & S): 2 Proven Evans Auxiliaries for Europe
When a chiral centre has to be set reliably, many process chemists still reach for an Evans auxiliary. 4-Phenyl-2-Oxazolidinone is one of the most widely used of these auxiliaries, and both of its enantiomers have become important again now that oral GLP-1 medicines such as orforglipron are moving into EuropeanContinue Reading
September 30, 2026
Lazertinib Key Starting Materials: 3 Proven Intermediates for Europe
Since the European Commission granted marketing authorisation to Lazcluze® (lazertinib) in January 2025, interest in its chemistry has grown steadily across Europe. For API developers, CDMOs and generic R&D teams, the first sourcing decision is always the same: which Lazertinib key starting materials to qualify, and from whom. This guideContinue Reading
September 12, 2026
Lazertinib Intermediate Manufacturer & Supplier: Europe & UK
Lazertinib Intermediate Supplier | CAS NO: 26033-20-5 Following the European Medicines Agency (EMA) marketing authorization of Lazcluze™ (Lazertinib) in combination with amivantamab for first-line treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) across the European Union, pharmaceutical manufacturers, CDMOs, and generic developers in Germany, the UnitedContinue Reading
September 9, 2026
Orforglipron Intermediate Supplier Europe & UK
High-Purity Orforglipron Intermediates: Direct Manufacturing Partner for UK & Europe The authorization of Orforglipron (Foundayo™) by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in August 2026 marked a historic turning point in the European pharmaceutical market. As the world’s first oral, non-peptide small-molecule GLP-1 receptor agonist authorized forContinue Reading
September 4, 2026
Lazertinib & Orforglipron Intermediates | Europe & UK
Lazertinib & Orforglipron Intermediates: Manufacturer & Supplier The global pharmaceutical landscape in 2026 is witnessing surging commercial demand for advanced small-molecule therapeutics. In the European Union and United Kingdom, two high-impact active pharmaceutical ingredients (APIs) dominate procurement and R&D pipelines: Lazertinib (Lazcluze™)—the 3rd-generation EGFR tyrosine kinase inhibitor approved by theContinue Reading